10.1 Non-Parenteral Medication Routes (Oral, Topical, Inhalation, Instillation)

10.1 Non-Parenteral Medication Routes (Oral, Topical, Inhalation, Instillation)

Medication administration is one of the highest-stakes clinical responsibilities performed by the Certified Medical Assistant (CMA). Non-parenteral medications encompass all pharmaceutical agents administered through routes other than direct tissue or vascular injection. These include enteral administration through the gastrointestinal tract, epidermal application through topical and transdermal systems, respiratory delivery through inhalation devices, and localized or systemic delivery through mucosal instillations.

To ensure absolute patient safety and therapeutic efficacy, the medical assistant must possess an exhaustive understanding of absorption mechanics, specialized administration techniques, patient positioning, and clinical risk mitigation protocols.

+--------------------------------------------------------------------------------------------------+
|                       THE CORE RIGHTS OF MEDICATION ADMINISTRATION                               |
+-----------------------+--------------------------------------------------------------------------+
| Right Patient         | Verify using two unique identifiers (full legal name and date of birth). |
| Right Medication      | Perform three label checks against the physician's order and EHR.        |
| Right Dose            | Calculate and verify precise dosage strength, volume, and unit.          |
| Right Route           | Ensure prescribed anatomical pathway matches the drug formulation.       |
| Right Time / Frequency| Administer at the exact scheduled interval or clinical timeframe.        |
| Right Documentation   | Record drug, dose, route, site, lot, exp date, and patient response.     |
| Right Reason          | Confirm indication matches the patient's clinical diagnosis.             |
| Right to Refuse       | Respect patient autonomy, educate on risks, and notify the provider.     |
+-----------------------+--------------------------------------------------------------------------+

---

1. Enteral & Oral Administration Routes

Enteral routes deliver medications directly into the gastrointestinal (GI) tract or through the oral mucosa. The primary enteral routes utilized in outpatient ambulatory care are oral (per os / PO), sublingual (SL), and buccal.

+--------------------------------------------------------------------------------------------------+
|                             ORAL AND TRANSMUCOSAL ROUTE MECHANICS                                |
+---------------------+-------------------------------+--------------------------------------------+
| Route               | Anatomical Placement          | Absorption Pathway & Hepatic First-Pass    |
+---------------------+-------------------------------+--------------------------------------------+
| Oral (PO)           | Swallowed into stomach / GI   | Absorbed via GI mucosa -> portal vein ->   |
|                     | tract with water              | undergoes extensive hepatic first-pass.    |
+---------------------+-------------------------------+--------------------------------------------+
| Sublingual (SL)     | Placed directly under tongue  | Rapid systemic capillary absorption via    |
|                     | on floor of mouth             | sublingual veins -> bypasses liver.        |
+---------------------+-------------------------------+--------------------------------------------+
| Buccal              | Placed between cheek and gum  | Transmucosal capillary absorption via      |
|                     | (upper/lower outer quadrant)  | buccal mucosa -> bypasses liver.           |
+---------------------+-------------------------------+--------------------------------------------+

Oral Route (PO — Per Os)

Oral administration is the most common, non-invasive, and cost-effective method of drug delivery. When swallowed, medications transit into the stomach and small intestine, where active ingredients are absorbed across the intestinal epithelium into the mesenteric venous circulation and transported via the hepatic portal vein directly to the liver. This process—known as hepatic first-pass metabolism—significantly metabolizes and reduces the bioavailable concentration of many drugs before they reach systemic circulation.

Clinical Administration Guidelines

1. Patient Positioning: Position the patient in a fully upright sitting position (High-Fowler's or seated in an examination chair) to prevent choking, dysphagia, and pulmonary aspiration. Never administer oral medications to a patient lying supine.
2. Fluid Intake: Provide 4 to 8 ounces (120–240 mL) of water to facilitate esophageal transit and dissolution, unless fluid-restricted or contraindicated.
3. Contraindications: Do not administer oral medications to patients who are unconscious, experiencing severe nausea/vomiting, designated NPO (nothing by mouth) for surgery, exhibiting active GI bleeding, or demonstrating severe dysphagia or absent gag reflexes.
4. Liquid Dosing Standards: When measuring liquid medications in a calibrated medicine cup, place the cup on a flat, level, eye-level surface. Read the volume at the lowest point of the liquid meniscus. Always use calibrated oral syringes for volumes under 5 mL or pediatric doses; never use domestic kitchen silverware.
5. Crushing & Splitting Restrictions: Medical assistants must NEVER crush, chew, or split Enteric-Coated (EC), Extended-Release (ER/XR/XL), Sustained-Release (SR), or Controlled-Release (CR) formulations. Enteric coatings protect the gastric mucosa from irritating compounds (e.g., aspirin) or protect acid-labile drugs from gastric acid degradation. Crushing extended-release tablets destroys the time-release matrix, resulting in "dose dumping," severe systemic toxicity, or fatal overdose.

Sublingual Route (SL)

Sublingual administration involves placing a tablet, spray, or dissolving film directly under the patient's tongue against the sublingual mucosa on the floor of the oral cavity.

• Pharmacological Mechanism: The sublingual space contains an extensive network of highly vascularized capillaries and thin non-keratinized epithelium. Active drug molecules diffuse directly into the sublingual and lingual veins, draining into the superior vena cava and entering systemic arterial circulation within 1 to 3 minutes. Sublingual delivery completely bypasses the gastrointestinal tract and hepatic first-pass metabolism.
• Representative Medication: Nitroglycerin (Nitrostat 0.3 mg, 0.4 mg, 0.6 mg) for acute angina pectoris.
• Patient Education & Technique:
  • Instruct the patient to lift their tongue and place the tablet on the floor of the mouth.
  • Instruct the patient to close their mouth and allow the tablet to dissolve naturally.
  • CRITICAL: Do NOT chew, swallow, or crush the tablet. Do not drink water, eat, or smoke until the tablet has completely dissolved.
  • Angina Protocol: Take 1 tablet SL at onset of chest pain. If pain persists or worsens after 5 minutes, call 911 immediately and take a second tablet. A maximum of 3 tablets may be taken in 15 minutes (5 minutes apart).

Buccal Route

Buccal administration involves placing the solid dosage form (tablet, lozenge, soluble film) in the lateral oral vestibule between the upper or lower gum and the inner mucosal lining of the cheek.

• Pharmacological Mechanism: Like sublingual delivery, buccal absorption occurs directly across the oral mucosa into systemic capillary beds, bypassing hepatic first-pass degradation.
• Representative Medications: Buccal midazolam (for refractory status epilepticus), fentanyl buccal tablets/lozenges (for breakthrough oncology pain), buccal testosterone.
• Patient Education & Technique: Instruct the patient to alternate cheeks with successive doses to avoid localized mucosal irritation. Do not chew, suck vigorously, or swallow the formulation. Withhold food and liquid until full dissolution occurs.

---

2. Topical and Transdermal Routes

Topical and transdermal routes apply medications directly to the cutaneous surface of the body. While topical preparations primarily target local skin pathology, transdermal therapeutic systems are engineered to achieve controlled, continuous, systemic drug absorption.

+--------------------------------------------------------------------------------------------------+
|                       TOPICAL VS. TRANSDERMAL PHARMACOLOGICAL PROFILE                            |
+---------------------+-------------------------------+--------------------------------------------+
| Characteristic      | Topical Preparations          | Transdermal Delivery Systems (Patches)     |
+---------------------+-------------------------------+--------------------------------------------+
| Formulations        | Creams, ointments, lotions,   | Multi-layered polymer matrix or reservoir  |
|                     | gels, pastes, liniments       | adhesive patches                           |
| Target Site         | Localized epidermis / dermis  | Systemic bloodstream via stratum corneum   |
| Systemic Absorption | Minimal / unintended          | Controlled, continuous, zero-order release |
| Clinical Examples   | Hydrocortisone, mupirocin     | Fentanyl, clonidine, scopolamine, nicotine |
+---------------------+-------------------------------+--------------------------------------------+

Topical Formulations (Creams, Ointments, Lotions)

• Ointments (Semisolid Oil-Based): 80% oil / 20% water emulsion. Provide an occlusive barrier that traps moisture; ideal for dry, chronic, scaly lesions (e.g., petrolatum, zinc oxide).
• Creams (Semisolid Water-Based): 50% water / 50% oil emulsion. Easily absorbed and cosmetically appealing; ideal for weeping or inflamed dermatological conditions.
• Lotions & Solutions (Liquid): Water-based suspensions or solutions; ideal for hair-bearing anatomical regions or large surface areas.
• Administration Technique: Always perform hand hygiene and don clean examination gloves. Cleanse the target skin area with mild soap and warm water, then pat completely dry. Dispense the ordered amount onto a sterile tongue depressor or gloved finger, and apply a thin, uniform film following the natural grain of hair growth. Never double-dip a tongue depressor into a multi-dose container.

Transdermal Therapeutic Systems (Patches)

Transdermal delivery systems consist of a backing layer, drug reservoir or matrix, rate-controlling membrane, and hypoallergenic adhesive. The drug diffuses through the lipid-rich stratum corneum at a constant, predictable rate into dermal microcirculation.

Mandatory Step-by-Step Transdermal Protocol

1. Locate & Remove Prior Patch: Inspect the patient's skin and locate any previously applied transdermal patch. Never apply a new patch without removing the old one first. Leaving multiple patches in place causes cumulative drug toxicity.
2. Dispose of Used Patch Safely: Peel off the old patch, immediately fold it in half with the sticky adhesive sides sealed firmly together, and dispose of it in a rigid sharps container or designated hazardous biohazard waste receptacle per OSHA and DEA guidelines. (Fentanyl patches retain up to 50% of active drug after 72 hours and can cause fatal respiratory depression in children or pets if discarded in open trash).
3. Cleanse & Dry Residual Site: Wipe away residual adhesive and medication from the old site with warm water and a soft cloth. Do not use alcohol wipes, as alcohol can dry the skin and enhance acute systemic absorption.
4. Select New Anatomical Site: Choose a clean, dry, intact, non-irritated, and relatively hairless site (upper outer arm, upper chest, upper back, or flank). Rotate anatomical sites with every patch change to prevent cutaneous sensitization and contact dermatitis.
5. Site Preparation: If hair is present, carefully clip the hair with scissors. NEVER shave the site with a razor, as microabrasions alter dermal permeability and accelerate drug absorption unpredictably.
6. Label the New Patch: Prior to application, write the Date, Time, and Medical Assistant's Initials on the outer backing of the patch using a soft felt-tip pen. Never use a sharp ballpoint pen, which can puncture the drug reservoir.
7. Apply Firm Pressure: Peel off the protective liner without touching the adhesive surface. Place the patch firmly on the skin and press down with the palm of the hand for 10 to 30 seconds, ensuring all edges adhere securely.
8. Document: Chart the exact anatomical location, date, time, dosage strength, and old patch removal in the EHR.

+--------------------------------------------------------------------------------------------------+
|                  CRITICAL BLACK BOX SAFETY WARNING: HEAT & TRANSDERMAL PATCHES                   |
+--------------------------------------------------------------------------------------------------+
| NEVER place heating pads, hot water bottles, electric blankets, saunas, or direct heat lamps   |
| over an active transdermal patch (especially Fentanyl, Clonidine, or Nitroglycerin).             |
| External heat induces severe cutaneous vasodilation and accelerates transdermal diffusion,      |
| causing rapid "dose dumping" into systemic circulation, profound toxicity, and fatal overdose.  |
+--------------------------------------------------------------------------------------------------+

---

3. Inhalation Medication Administration

Inhalation routes deliver micronized aerosol droplets or dry powder particles directly into the tracheobronchial tree and alveolar capillaries. Inhalation achieves a rapid local onset of action for pulmonary disorders (asthma, COPD) while minimizing systemic adverse effects.

+--------------------------------------------------------------------------------------------------+
|                             INHALATION DEVICE COMPARISON & PROTOCOLS                             |
+-------------------+------------------------------+-----------------------------------------------+
| Device Type       | Physical Mechanism           | Key Administration Technique                  |
+-------------------+------------------------------+-----------------------------------------------+
| Metered-Dose      | Chemical propellant pushes   | Shake 5s; slow, deep inhalation (3-5s); hold  |
| Inhaler (MDI)     | measured liquid aerosol mist | breath 10s; wait 1-2 min between puffs.       |
+-------------------+------------------------------+-----------------------------------------------+
| MDI with Spacer / | Chamber holds aerosol cloud; | Eliminates hand-breath coordination; maximizes|
| Holding Chamber   | one-way valve controls flow  | alveolar deposition; reduces oral thrush.     |
+-------------------+------------------------------+-----------------------------------------------+
| Dry Powder        | Breath-actuated; micronized  | No shaking; rapid, forceful, deep inhalation; |
| Inhaler (DPI)     | dry powder capsule/disk      | do not exhale into mouthpiece.                |
+-------------------+------------------------------+-----------------------------------------------+
| Small-Volume      | Compressed air / ultrasonic  | Continuous normal tidal breathing with        |
| Nebulizer (SVN)   | creates fine aerosol mist    | mouthpiece over 10-15 minutes.                |
+-------------------+------------------------------+-----------------------------------------------+

Metered-Dose Inhalers (MDI)

MDIs utilize a chemical propellant (hydrofluoroalkane, HFA) to expel a calibrated dose of liquid medication upon canister depression.

MDI Step-by-Step Technique

1. Inspect mouthpiece for foreign objects and ensure canister is firmly seated.
2. Shake the inhaler vigorously for 5 seconds (ensures homogenous suspension).
3. Instruct the patient to sit upright and exhale completely away from the device.
4. Position the inhaler: Place mouthpiece in mouth between teeth with lips sealed tightly around it, OR hold 1 to 2 inches (2–4 cm) in front of an open mouth, OR attach a spacer.
5. Instruct patient to begin inhaling slowly and deeply through the mouth, and simultaneously depress the canister once.
6. Continue a slow, deep inhalation over 3 to 5 seconds.
7. Instruct the patient to hold their breath for 10 seconds (or as long as comfortable) to allow aerosol particles to settle onto bronchial walls.
8. Exhale gently through pursed lips.
9. If a second puff of the same medication is ordered, wait 1 to 2 minutes before administering the next puff to allow the airway to accommodate.

Spacers and Valved Holding Chambers

A spacer is an extension tube that attaches to the MDI mouthpiece. When the canister is actuated, the medication enters the chamber and remains suspended for several seconds.

• Clinical Advantages: Eliminates the necessity for precise hand-breath coordination. Slows particle velocity and traps large droplets, decreasing drug deposition in the posterior pharynx (reducing systemic absorption and hoarseness) while increasing alveolar lung delivery from ~10% up to 30%.

Inhaler Sequencing: Bronchodilator Before Corticosteroid

When both a short-acting bronchodilator (e.g., Albuterol) and an inhaled corticosteroid (e.g., Fluticasone, Budesonide) are prescribed:

1. Administer the Bronchodilator FIRST: The beta-2 agonist dilates the smooth muscle of the bronchial tree.
2. Wait 5 Minutes: Allow airway dilation to occur.
3. Administer the Corticosteroid SECOND: The widened bronchial lumen permits deeper penetration and maximum distribution of the anti-inflammatory steroid into lower airways.
4. CRITICAL Post-Steroid Mouth Rinsing: Immediately following inhaled corticosteroid administration, the patient must rinse their mouth thoroughly with water and spit it out (do not swallow). Rinsing removes residual steroid deposits from the oropharynx, preventing oral candidiasis (thrush) and dysphonia (hoarseness).

Dry Powder Inhalers (DPI) & Small-Volume Nebulizers (SVN)

• Dry Powder Inhalers (e.g., Advair Diskus, Spiriva HandiHaler): Breath-activated devices requiring no propellant. Instruct the patient to exhale completely away from the inhaler, seal lips around mouthpiece, and inhale rapidly, forcefully, and deeply. Never shake a DPI or exhale moisture into the mouthpiece.
• Small-Volume Nebulizers: Driven by a compressed oxygen/air machine that aerosolizes 3 to 5 mL of liquid medication into a continuous fine mist. The patient breathes slowly and deeply with a mouthpiece or tight-fitting pediatric mask over 10 to 15 minutes until the chamber sputters.

---

4. Instillations and Enteral Mucosal Routes

Instillations deliver liquid medications into mucosal body cavities. These require strict aseptic protocols, correct patient positioning, and anatomical alignment.

+--------------------------------------------------------------------------------------------------+
|                       SPECIALIZED INSTILLATION TECHNIQUES & ANATOMICAL RULES                     |
+--------------------+------------------------------+----------------------------------------------+
| Route              | Anatomical Positioning       | Key Procedural Step / Rationale              |
+--------------------+------------------------------+----------------------------------------------+
| Ophthalmic Drops   | Head tilted back, looking up | Lower conjunctival fornix; 1-2 min punctal   |
|                    |                              | occlusion at inner canthus (blocks systemic).|
+--------------------+------------------------------+----------------------------------------------+
| Ophthalmic Ointment| Head tilted back, looking up | 1/2-inch ribbon inner to outer fornix;       |
|                    |                              | warn patient about temporary blurred vision. |
+--------------------+------------------------------+----------------------------------------------+
| Otic (Adults / >3y)| Head tilted / side-lying     | Pull auricle UP and BACK; warm solution to   |
|                    |                              | prevent caloric vertigo; stay 3-5 minutes.   |
+--------------------+------------------------------+----------------------------------------------+
| Otic (Child <3 yr) | Head tilted / side-lying     | Pull auricle DOWN and BACK; straightens the  |
|                    |                              | shorter, horizontal cartilaginous canal.     |
+--------------------+------------------------------+----------------------------------------------+
| Nasal Drops/Sprays | Upright, tilted forward      | Spray directed laterally toward ear, away    |
|                    | (sprays) or back (drops)     | from midline nasal septum.                   |
+--------------------+------------------------------+----------------------------------------------+
| Rectal Suppository | Left lateral Sims' position  | Water-soluble lube; insert past sphincter    |
|                    | (right leg flexed)           | (1" child, 2" adult); retain 15-20 min.      |
+--------------------+------------------------------+----------------------------------------------+
| Vaginal Cream/Supp | Dorsal recumbent / lithotomy | Calibrated applicator; bedtime (qhs) dosing  |
|                    | with knees flexed            | prevents gravity drainage.                   |
+--------------------+------------------------------+----------------------------------------------+

Ophthalmic Instillation (Eye Drops and Ointments)

Ophthalmic medications must be completely sterile and clearly labeled "For Ophthalmic Use."

Eye Drop Administration Protocol

1. Verify physician order and wash hands; don clean gloves.
2. Have the patient sit or recline with their head tilted backward, looking toward the ceiling.
3. Using a clean tissue held against the patient's cheekbone, place the non-dominant thumb or index finger below the lower lid and pull downward to expose the lower conjunctival sac (fornix).
4. Hold the dropper bottle vertically 0.5 to 0.75 inches above the eye. Never touch the dropper tip to the eye, eyelashes, or skin (maintains sterility).
5. Instill the exact number of drops into the outer third of the lower conjunctival fornix. Never drop medication directly onto the sensitive cornea, which triggers a painful blink reflex.
6. Instruct the patient to close their eyelids gently without squeezing or rubbing.
7. Perform Nasolacrimal Punctal Occlusion: Apply gentle pressure with sterile gauze over the inner canthus (nasolacrimal duct) for 1 to 2 minutes. This prevents the liquid from draining down the tear duct into the nasal mucosa where rapid systemic vascular absorption occurs (critical for ophthalmic beta-blockers like timolol to prevent systemic bradycardia and hypotension).
8. If administering multiple ophthalmic drops, wait 5 minutes between different medications.

Eye Ointment Administration

Squeeze a thin 0.5-inch ribbon of ointment along the inner to outer margin of the lower conjunctival sac. Discard the first bead of ointment before application. Warn the patient that vision will be temporarily blurred for several minutes.

Otic Instillation (Ear Drops)

Otic drops must be labeled "For Otic Use." Administering cold ear drops triggers the caloric reflex, inducing severe dizziness, nystagmus, nausea, and vomiting.

Otic Administration Protocol

1. Warm the Solution: Hold the medication bottle in the palms of the hands for 1 to 2 minutes to bring the liquid to body temperature (98.6°F / 37°C).
2. Position Patient: Place the patient in a lateral recumbent position (side-lying) with the affected ear facing upward, or seated with head tilted sideways.
3. Auricle (Pinna) Manipulation:
   • Adults and Children Over 3 Years: Pull the pinna UP and BACK.
   • Infants and Children Under 3 Years: Pull the pinna DOWN and BACK.
   • Rationale: Pulling the pinna in the correct anatomical direction straightens the S-shaped external auditory canal, allowing drops to flow directly toward the tympanic membrane.
4. Instill Drops: Direct drops along the side wall of the ear canal rather than dropping directly onto the tympanic membrane.
5. Post-Instillation: Gently massage the tragus with a circular motion to facilitate medication movement. Have the patient remain in the side-lying position for 3 to 5 minutes. A loose cotton pledget may be placed in the meatus for 15 minutes if ordered; do not pack tightly.

Nasal Instillation (Sprays and Drops)

• Nasal Sprays: Patient sits upright with head tilted slightly forward. Insert nozzle into one nostril, occlude opposite nostril with finger, and direct nozzle laterally toward the outer ear (away from the central nasal septum to avoid mucosal ulceration and septal perforation). Instruct patient to inhale gently through nose while depressing the pump.
• Nasal Drops: Patient in supine position with head tilted backward over the edge of the exam table (Proetz position for ethmoid/sphenoid sinuses, Parkinson position for maxillary/frontal sinuses).

Rectal Administration (Suppositories and Enemas)

• Indications: Antiemetics (promethazine), antipyretics (acetaminophen), analgesics, laxatives, when oral route is compromised by severe emesis or unconsciousness.
• Positioning: Place patient in Left Lateral Sims' Position (lying on left side with left leg extended and right knee/thigh flexed upward toward chest). This anatomical orientation aligns with the descending colon and sigmoid flexure.
• Technique: Don gloves. Lubricate the pointed apex of the suppository and gloved index finger with water-soluble lubricant (never petroleum jelly). Instruct patient to take slow deep breaths to relax the anal sphincter. Gently insert suppository pointed end first past the internal anal sphincter (approx. 1 inch in infants/children, 2 inches in adults). Instruct patient to remain in position and retain suppository for 15 to 20 minutes for systemic absorption.

Vaginal Administration (Creams, Tablets, Suppositories)

• Indications: Antifungal therapies (miconazole), antibacterial agents (metronidazole), hormonal replacement (estrogen cream).
• Positioning & Technique: Patient in dorsal recumbent or lithotomy position. Fill calibrated applicator, lubricate tip with water-soluble gel, insert gently into vaginal vault downward and backward 2 to 3 inches, and depress plunger. Administer at bedtime (qhs) to maximize mucosal contact time and prevent gravitational loss when standing.

Non-Parenteral Routes & Administration Techniques